Vator Securities advises SciBase on 71 MSEK Directed Share Issues
Vator Securities acts as Sole Bookrunner in connection with the transactions raising SEK approximately SEK 71 million.
The share issues are directed to a number of Swedish and international investors, including Van Herk Investments B.V. and ÖstVäst Capital Management, amongst others.
Read MoreFour new partners at Vator Securities
Vator Securities was established ten years ago and continues to expand. Hereby the promotion of four employees to new partners is announced: Erik Sjöström, Erik Röjvall, Felicia Rittemar, and Anders Arviken.
Through our new partners, Vator Securities further broadens and strengthens our knowledgebase. Acceding partners contribute with many years of professional experience and broad knowledge about, among other things, share analysis, project management, investment activities, and share management.
Read MoreVator Tech Days – Focus: Gaming
Vator Securities welcomes you to Vator Tech Days – Focus: Gaming, a digital event where you get the opportunity to meet the most exciting fast-growing companies within Gaming and Esport.
The event takes place on May 26th at 09:00 to 16:45. Among the participating companies are Modern Times Group, Enad Global 7, Media and Games Invest, Thunderful Group, 11 Bit Studios (PL), Epulze, Flexion, Adverty, Qiiwi, Safe Lane Gaming, and MAG Interactive.
Read MoreVator Securities advises Respiratorius on 25 MSEK Directed Share Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million.
Respiratorius AB is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.
Read MoreVator Securities advises Sprint Bioscience on 21 MSEK Directed Share Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 21 million.
Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. With a fragment-based drug development method, the company develops drug projects in a time- and resource-efficient way that is outlicensed to global pharmaceutical companies during the preclinical phase.
Read MoreVator Securities advises Epulze on 57 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 57 million.
Epulze gives amateur players of computer games like Dota 2 and Counter-Strike: Global Offensive, the opportunity to participate in tournaments, leagues, and matches where real money is at stake. Among the new investors are well-known names such as Svea Ekonomi and Norwegian Carucel Finance, while Knutsson Holdings increases its ownership in the company.
Read MoreVator Securities advises CombiGene on 75 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 75 million.
Having established the production platform for CG01, CombiGene’s intention in 2021 is to focus on the final parts of the preclinical program for CG01 with two major preclinical studies, a biodistribution study and a safety study, which will be conducted together with CombiGene’s CRO partners Northern Biomedical Research and Neurochase.
Read MoreVator Securities Events
Vator Securities Tech Days are investor events with some of the most interesting and fast-growing tech companies in the Nordics.
Vator Securities presents a focused insight into the spectrum of tech companies including expert sessions related to the tech industry.
Read More